IMMUNOVANT INC's ticker is IMVT and the CUSIP is 45258J102. A total of 97 filers reported holding IMMUNOVANT INC in Q2 2022. The put-call ratio across all filers is 0.07 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $600,000 | -11.6% | 107,498 | -38.2% | 0.26% | -11.1% |
| Q2 2022 | $679,000 | -12.3% | 174,000 | +23.8% | 0.29% | -1.7% |
| Q1 2022 | $774,000 | -35.3% | 140,500 | 0.0% | 0.29% | -32.9% |
| Q4 2021 | $1,197,000 | -2.0% | 140,500 | 0.0% | 0.44% | -7.2% |
| Q3 2021 | $1,221,000 | +80.6% | 140,500 | +119.5% | 0.47% | +72.4% |
| Q2 2021 | $676,000 | – | 64,000 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alpine Global Management, LLC | 4,448,017 | $17,347,000 | 4.39% |
| Deep Track Capital, LP | 9,455,000 | $36,875,000 | 2.42% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 233 | $60,000,000 | 0.63% |
| Octagon Capital Advisors LP | 579,061 | $2,258,000 | 0.60% |
| Eventide Asset Management | 5,372,512 | $20,953,000 | 0.45% |
| WITTENBERG INVESTMENT MANAGEMENT, INC. | 174,000 | $679,000 | 0.29% |
| Frazier Life Sciences Management, L.P. | 585,759 | $2,284,000 | 0.22% |
| BCK CAPITAL MANAGEMENT LP | 54,293 | $212,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 777,590 | $3,033,000 | 0.12% |
| Bridgefront Capital, LLC | 15,649 | $61,000 | 0.07% |